D1306
地异喹 硫酸酯
powder, ≥98% (TLC)
别名:
3,4-二氢-2（1H）-异喹啉羧酰亚胺, Ro 5-33071, 去甲异喹 硫酸酯
产品名称
地异喹 硫酸酯,
方案
≥98% (TLC)
质量水平
表单
powder
mp
285 °C
溶解性
H2O: 20 mg/mL (with heat)
储存温度
room temp
SMILES字符串
OS(O)(=O)=O.NC(=N)N1CCc2ccccc2C1.NC(=N)N3CCc4ccccc4C3
InChI
1S/2C10H13N3.H2O4S/c2*11-10(12)13-6-5-8-3-1-2-4-9(8)7-13;1-5(2,3)4/h2*1-4H,5-7H2,(H3,11,12);(H2,1,2,3,4)
InChI key
CAYGYVYWRIHZCQ-UHFFFAOYSA-N
基因信息
human ... SLC6A2(6530)
正在寻找类似产品? 访问 产品对比指南
一般描述
细胞色素P450 CYP2D6的底物； 细胞色素P450基因多态性的指示剂。
生化/生理作用
去异喹酮是一种抗高血压药。它可由细胞色素P4502D6所代谢。
警示用语：
Warning
危险声明
预防措施声明
危险分类
Acute Tox. 4 Oral
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
dust mask type N95 (US), Eyeshields, Gloves
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
N E Caporaso et al.
Environmental health perspectives, 98, 101-105 (1992-11-01)
Debrisoquine is an antihypertensive drug that is metabolized by cytochrome P4502D6. Deficient metabolism is inherited as an autosomal recessive condition. We previously reported in a case-control study that extensive metabolizers of debrisoquine were at greater risk of lung cancer compared
E Jacqz-Aigrain et al.
Biochemical pharmacology, 41(11), 1657-1663 (1991-06-01)
Interindividual variations of debrisoquine metabolism was recently identified in non-human primates tested in vivo. The catalytical and immunological characterization of cytochrome P450IID subfamily was undertaken in hepatic microsomes from extensive metabolizer primates. The NADPH/O2 mediated metabolism of debrisoquine, dextromethorphan and
Ping-Ching Hsu et al.
Molecular carcinogenesis, 56(2), 594-606 (2016-06-25)
Smoking-related biomarkers for lung cancer and other diseases are needed to enhance early detection strategies and to provide a science base for tobacco product regulation. An untargeted metabolomics approach by ultra-performance liquid chromatography-quadrupole-time of flight mass spectrometry (UHPLC-Q-TOF MS) totaling
J W Ho et al.
Analytical biochemistry, 203(2), 348-351 (1992-06-01)
Debrisoquine and sparteine are prototype substrates of a genetic deficiency in cytochrome P450-dependent drug metabolism. Sensitive assays of in vitro oxidation of sparteine and debrisoquine are required for evaluation of this polymorphism. The activities were measured by quantitative analysis of
E Scarr et al.
Progress in neuro-psychopharmacology & biological psychiatry, 15(2), 297-301 (1991-01-01)
1. Studies were carried out on three monoamine oxidase (MAO) inhibitors, two of which, debrisoquine and para- hydroxyphenelzine, are purported to be peripheral inhibitors and one, phenelzine, is a peripherally acting inhibitor, which has been included for comparitive purposes. 2.
商品
一期生物转化反应在药物上引入或暴露官能团，目的是增加化合物的极性。尽管一期药物代谢发生在大多数组织中，但代谢的主要和首过部位发生在肝循环期间。
Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持